Value
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.5 |
| P/S | 9.1 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 3.8 |
| PEG | 8.2 |
| Analyst target | 4.0 |
- ▸Forward P/E: 30.9x
- ▸PEG: 0.79
GRDN · Why this verdict
Why Guardian Pharmacy Services (GRDN) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is running at 126% of net income—a premium cash conversion ratio—and return on equity is 27%, indicating the business is generating significantly more cash than it reports in earnings and deploying capital at above-average rates of return. Quality | Free cash flow conversion stays above 100% of net income for 2 consecutive reported quarters, confirming the cash generation quality is structural rather than one-time. | →Stable |
| CounterA 31.6x forward earnings multiple implies the market has already priced in the quality premium; at that valuation the cash conversion ratio and return on equity must not only persist but improve to justify further multiple expansion, leaving no margin for any operating setback. | ||
After one in-line quarter, the company has delivered three consecutive quarterly earnings beats with an average positive surprise of roughly 17%—demonstrating consistent execution and management's ability to systematically exceed analyst expectations. Earnings | EPS beats consensus for 2 of the next 2 reported quarters, extending the streak to 5 consecutive beats. | →Stable |
| CounterThe in-line quarter at the oldest position in the recent history shows the beat record is not unbroken; a business with concentrated customer exposure can experience lumpy quarterly outcomes that disrupt the consistency pattern without signaling a broader deterioration. | ||
At $42.88, the stock is just below its near-term take-profit level of $43.08—only 0.5% of headroom remains—and the risk/reward ratio of approximately 0.07-to-1 is deeply unfavorable, meaning almost all of the near-term technical upside has already been captured. Price targets | Price pulls back below $39, restoring at least 10% of potential upside to the take-profit level and resetting the reward/risk geometry to a level more appropriate for new entry. | →Stable |
| CounterA stock holding near its technical ceiling with strong momentum and institutional accumulation can break out to a new, higher equilibrium if the next earnings print triggers an analyst price target revision upward. | ||
Revenue is concentrated in a specific segment of long-term care facility residents, creating a scenario where any adverse regulatory, reimbursement, or demographic shift within that narrow customer segment could disproportionately impact the business with limited ability to diversify quickly. Bear case | The company adds at least 1 meaningful new customer segment or care-setting type within 12 months, reducing reliance on a single customer category. | →Stable |
| CounterDeep specialization in a single care segment can create operational efficiencies, pricing leverage, and switching costs that generate above-average retention rates; the concentrated focus may be a source of competitive advantage rather than a structural vulnerability. | ||
Institutional holders are in aggregate accumulating the stock, as reflected in a maximum holder-change reading—indicating that well-resourced, long-horizon investors are increasing exposure, which typically precedes or accompanies fundamental re-rating. Insider | Institutional ownership continues expanding for 2 consecutive 13F filing periods, confirming the accumulation trend is sustained rather than a temporary positioning event. | →Stable |
| CounterInstitutional accumulation is a lagging and noisy signal—13F data is reported with a delay and aggregated accumulation can coexist with overbought conditions at a stock-specific level; at a 31.6x forward multiple and with the stock near its 52-week high, new institutional buyers may face diminishing returns. | ||
Free cash flow is running at 126% of net income—a premium cash conversion ratio—and return on equity is 27%, indicating the business is generating significantly more cash than it reports in earnings and deploying capital at above-average rates of return.
→StableQuality
- Expectation
- Free cash flow conversion stays above 100% of net income for 2 consecutive reported quarters, confirming the cash generation quality is structural rather than one-time.
CounterA 31.6x forward earnings multiple implies the market has already priced in the quality premium; at that valuation the cash conversion ratio and return on equity must not only persist but improve to justify further multiple expansion, leaving no margin for any operating setback.
After one in-line quarter, the company has delivered three consecutive quarterly earnings beats with an average positive surprise of roughly 17%—demonstrating consistent execution and management's ability to systematically exceed analyst expectations.
→StableEarnings
- Expectation
- EPS beats consensus for 2 of the next 2 reported quarters, extending the streak to 5 consecutive beats.
CounterThe in-line quarter at the oldest position in the recent history shows the beat record is not unbroken; a business with concentrated customer exposure can experience lumpy quarterly outcomes that disrupt the consistency pattern without signaling a broader deterioration.
At $42.88, the stock is just below its near-term take-profit level of $43.08—only 0.5% of headroom remains—and the risk/reward ratio of approximately 0.07-to-1 is deeply unfavorable, meaning almost all of the near-term technical upside has already been captured.
→StablePrice targets
- Expectation
- Price pulls back below $39, restoring at least 10% of potential upside to the take-profit level and resetting the reward/risk geometry to a level more appropriate for new entry.
CounterA stock holding near its technical ceiling with strong momentum and institutional accumulation can break out to a new, higher equilibrium if the next earnings print triggers an analyst price target revision upward.
Revenue is concentrated in a specific segment of long-term care facility residents, creating a scenario where any adverse regulatory, reimbursement, or demographic shift within that narrow customer segment could disproportionately impact the business with limited ability to diversify quickly.
→StableBear case
- Expectation
- The company adds at least 1 meaningful new customer segment or care-setting type within 12 months, reducing reliance on a single customer category.
CounterDeep specialization in a single care segment can create operational efficiencies, pricing leverage, and switching costs that generate above-average retention rates; the concentrated focus may be a source of competitive advantage rather than a structural vulnerability.
Institutional holders are in aggregate accumulating the stock, as reflected in a maximum holder-change reading—indicating that well-resourced, long-horizon investors are increasing exposure, which typically precedes or accompanies fundamental re-rating.
→StableInsider
- Expectation
- Institutional ownership continues expanding for 2 consecutive 13F filing periods, confirming the accumulation trend is sustained rather than a temporary positioning event.
CounterInstitutional accumulation is a lagging and noisy signal—13F data is reported with a delay and aggregated accumulation can coexist with overbought conditions at a stock-specific level; at a 31.6x forward multiple and with the stock near its 52-week high, new institutional buyers may face diminishing returns.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A pharmacy services provider with excellent cash conversion (126% of net income), 27% return on equity, three consecutive quarterly earnings beats, and growing institutional ownership trades just below its near-term technical target with only 0.5% headroom remaining—creating a favorable long-term quality picture but an unfavorable near-term entry geometry at current prices.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 9.0 |
| ROA | 9.6 |
| Gross margin | 0.2 |
| Op margin | 2.5 |
| Net margin | 1.8 |
| Current ratio | 5.4 |
| FCF quality | 9.2 |
| Moat | 6.4 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 27%
- ▸Excellent cash conversion: 126% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
6.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.0 |
| EPS growth | 9.8 |
Momentum
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 2.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.6 |
| Price target | 6.7 |
- ▸Light analyst coverage (6.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.6 |
| quality rank | 6.0 |
| growth rank | 2.0 |
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.1 |
| support resistance | 3.4 |
| 52w position | 9.1 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.6 |
| days to cover | 1.9 |
| volatility | 0.3 |
| put call | 0.0 |
| implied vol | 3.0 |
| debt equity | 9.3 |
- ▸Elevated put/call: 6.00
- ▸High IV: 62%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- MOMENTUM:6.1>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.3=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.27
Upside
-2.6%
Downside
9.8%
Sizing output
AVOID
SetupRange Bound — RSI 46 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.7B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.1>=5.5. Top dim: Insider at 7.3; weakest: Peer rank at 2.4. No conviction either direction.
The strongest dimensions are Insider at 7.3, Sentiment at 7.0, and Catalyst at 7.0; the weakest are Peer rank at 2.4, Risk (lower is worse) at 3.4, and Value at 4.7. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Cash Conversion
Trip ifFree cash flow as a percentage of net income falls below 80% for 2 consecutive reported quarters, indicating deterioration in the premium cash conversion quality.
- P2Earnings Beat Streak Consistency
Trip ifEPS surprise falls below 0% (a miss) for 2 consecutive reported quarters, ending the beat streak.
- P3Price At Technical Ceiling
Trip ifPrice falls below $39, restoring more than 10% potential upside to the take-profit level and resetting the reward/risk to at least 1.5-to-1 favorable.
- P4Customer Concentration Risk
Trip ifAt least 1 new meaningful customer care-setting or customer segment is announced within 12 months, reducing single-segment concentration below its current level.
- P5Institutional Accumulation Signal
Trip ifInstitutional ownership falls below its prior-period level in each of 2 consecutive 13F filing periods (approximately 6 months), reversing the accumulation signal.